The University of Texas MD Anderson Cancer Center — Houston, Texas

Public research footprint of The University of Texas MD Anderson Cancer Center, compiled from the ClinicalTrials.gov public registry.

710

Registered studies

280

Active

180

Recruiting now

252

Completed

154

Stopped or withdrawn

Most-studied conditions

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma (PDAC) · Relapsed/Refractory Follicular Lymphoma · Low Grade Upper Tract Urothelial Carcinoma

Recently updated registry entries

NCT07185997 — Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's… (Recruiting)
NCT07265947 — Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract… (Recruiting)
NCT03869190 — Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… (Terminated)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at The University of Texas MD Anderson Cancer Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.